AMERSA

AMERSA

Call Us: (401) 615-4047 | Contact Us AMERSA on Twitter AMERSA on LinkedIn AMERSA on BlueSky

Make a Donation Pay a Past-Due Balance Join Our Mailing List
  • About
    • What is AMERSA
    • Board of Directors
    • Donate to AMERSA
    • Contact Us
  • Membership
    • Get to Know AMERSA
    • Join / Renew
    • Who We Are
    • Member Center
    • Special Interest Groups
    • Career Opportunities
    • Professional & Academic Advancement Opps
  • Conference
    • Annual Conference
    • Conference Sponsorship
    • Conference Exhibitor Information
    • Policy and Procedures for AMERSA Events
    • 2024 Conference Materials
    • Past Conference Resources
  • Journal
    • Journal Home
    • About Us
    • Member Access to Journal
    • Author Instructions and Submission
    • SAj Blog
    • SAj Annual Awards
    • SAj Editorial Scholar Program
  • Advocacy
    • AMERSA Advocacy
    • Position Statements
    • Submit a Position Statement
    • Letters of Support
    • Public Comments
  • Sustainability
    • Initiatives
    • Resources
  • Education
    • AMERSA Podcast Series
    • AMERSA Webinars
    • Core Competencies – AMERSA in the 21st Century
    • Resources
  • Awards
    • AMERSA Awards
    • Current Award Winners
    • Past Award Winners

The Authors’ Own Words: Co-prescription of naloxone as a Universal Precautions model for patients on chronic opioid therapy—Observational study

Sep 20, 2017 by AMERSA

We ask authors to describe their impressions regarding the implications of their accepted work, how their findings will change practice, and what is noteworthy about the work.

Co-prescription of naloxone as a Universal Precautions model for patients on chronic opioid therapy—Observational study
Mikiko Y. Takeda, Joanna G. Katzman, Ernest Dole, Melissa Heinz Bennett, Amal Alchbli, Daniel Duhigg & Howard Yonas
Substance Abuse Vol. 37 , Iss. 4,2016

Since opioid overdose death is such a pressing public health issue, harm reduction innovations to prevent overdose death are critical to study. The ambulatory co-prescribing of naloxone is a universal precaution model for all patients prescribed chronic opioid therapy. This can be adapted universally for all patients treated with chronic opioid therapy in an ambulatory setting so that there is increased availability and utilization in the case of an opioid overdose.

————————————————————————————————-
Our newly released issue is now online —> April-June 2017.
————————————————————————————————
–

Filed Under: SAj Blog, The Authors' Own Words, Uncategorized

Copyright © 2025
Site by: web360